相似文献
1
Advances in Lung Cancer Imaging and Therapy.
Cancers (Basel). 2021 Dec 23;14(1):58. doi: 10.3390/cancers14010058.
2
A systematic review and meta-analysis of the prognostic value of radiomics based models in non-small cell lung cancer treated with curative radiotherapy.
Radiother Oncol. 2021 Feb;155:188-203. doi: 10.1016/j.radonc.2020.10.023. Epub 2020 Oct 21.
3
Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Respir Res. 2021 Jun 28;22(1):189. doi: 10.1186/s12931-021-01780-2.
5
F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival.
Cancers (Basel). 2020 May 5;12(5):1163. doi: 10.3390/cancers12051163.
6
Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients.
Thorac Cancer. 2020 Apr;11(4):964-972. doi: 10.1111/1759-7714.13349. Epub 2020 Feb 15.
7
Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Cancer Med. 2021 Feb;10(4):1222-1239. doi: 10.1002/cam4.3718. Epub 2021 Jan 19.
8
Prediction of radiation pneumonitis after definitive radiotherapy for locally advanced non-small cell lung cancer using multi-region radiomics analysis.
Sci Rep. 2021 Aug 10;11(1):16232. doi: 10.1038/s41598-021-95643-x.
9
Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Cancer Prev Control. 1997 Dec;1(5):366-78.
10
Measurement Variability in Treatment Response Determination for Non-Small Cell Lung Cancer: Improvements Using Radiomics.
J Thorac Imaging. 2019 Mar;34(2):103-115. doi: 10.1097/RTI.0000000000000390.
本文引用的文献
1
Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [F]FDG PET/CT in Metastatic Melanomas and Lung Cancer.
J Clin Med. 2021 Nov 3;10(21):5160. doi: 10.3390/jcm10215160.
2
Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials.
Cancers (Basel). 2021 Sep 9;13(18):4533. doi: 10.3390/cancers13184533.
3
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab.
Cancers (Basel). 2021 Jun 22;13(13):3117. doi: 10.3390/cancers13133117.
4
Whole-Lesion Apparent Diffusion Coefficient Histogram Analysis: Significance for Discriminating Lung Cancer from Pulmonary Abscess and Mycobacterial Infection.
Cancers (Basel). 2021 May 31;13(11):2720. doi: 10.3390/cancers13112720.
5
Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer.
Cancers (Basel). 2021 May 13;13(10):2352. doi: 10.3390/cancers13102352.
6
Non-Small-Cell Lung Cancer: New Rare Targets-New Targeted Therapies-State of The Art and Future Directions.
Cancers (Basel). 2021 Apr 12;13(8):1829. doi: 10.3390/cancers13081829.
7
Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience.
Cancers (Basel). 2021 Apr 1;13(7):1634. doi: 10.3390/cancers13071634.
8
Impact of Low-Dose Irradiation of the Lung and Heart on Toxicity and Pulmonary Function Parameters after Thoracic Radiotherapy.
Cancers (Basel). 2020 Dec 23;13(1):22. doi: 10.3390/cancers13010022.
9
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab.
Cancers (Basel). 2020 Aug 10;12(8):2234. doi: 10.3390/cancers12082234.
10
The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
J Cancer Res Clin Oncol. 2020 May;146(5):1235-1243. doi: 10.1007/s00432-020-03150-9. Epub 2020 Feb 11.
Zotero 插件